Pharmacological Research (May 2024)

The major histocompatibility complex participates in Parkinson’s disease

  • Rou Gu,
  • Jianyu Pan,
  • Maher Un Nisa Awan,
  • Xiaowei Sun,
  • Fang Yan,
  • Liping Bai,
  • Jie Bai

Journal volume & issue
Vol. 203
p. 107168

Abstract

Read online

Parkinson’s disease (PD) is a common neurodegenerative disease characterized by progressive loss of dopaminergic neurons in the substantia nigra and the aggregation of alpha-synuclein (α-syn). The central nervous system (CNS) has previously been considered as an immune-privileged area. However, studies have shown that the immune responses are involved in PD. The major histocompatibility complex (MHC) presents antigens from antigen-presenting cells (APCs) to T lymphocytes, immune responses will be induced. MHCs are expressed in microglia, astrocytes, and dopaminergic neurons. Single nucleotide polymorphisms in MHC are related to the risk of PD. The aggregated α-syn triggers the expression of MHCs by activating glia cells. CD4+ and CD8+ T lymphocytes responses and microglia activation are detected in brains of PD patients. In addiction immune responses further increase blood-brain barrier (BBB) permeability and T cell infiltration in PD. Thus, MHCs are involved in PD through participating in immune and inflammatory responses.

Keywords